Return to Directory

Metabolix-3

Technical Monograph

Metabolix-3 is a high-potency investigational triple-agonist. Modeled heavily on current triple-incretin architectures (GIP, GLP-1, and Glucagon Receptor agonism), it is studied for profound systemic metabolic reconfiguration.

Mechanism of Action

Simultaneously agonizes three critical metabolic pathways: GLP-1 (satiety/insulin secretion), GIP (satiety/fat modification), and Glucagon (hepatic lipid burning and basal metabolic rate elevation).

Pharmacological Detail

The addition of glucagon agonism serves as a direct catabolic driver, forcing adipocytes and hepatocytes to mobilize fat for energy while the incretin mechanisms suppress appetite.

Pharmacodynamics

Demonstrates highly synergistic reductions in mass markers, surpassing dual-agonism in preclinical benchmarking.

Pharmacokinetics

Utilizes advanced fatty acid attachment chemistry, ensuring stable plasma concentrations for weekly application frequency.

Preclinical Observations & In Vitro Data

Derived from the foundational pathways documented in TRIUMPH phase trials. Represents state-of-the-art multi-receptor metabolic research. Data cited from published literature.

Triple Pathway Analysis (Preclinical): Marked reductions in mass trajectories compared to dual-agonists.

Abstract Highlights

  • Concurrent activation of three metabolic signaling axes
  • Observations of unprecedented mass parameter reduction in models
  • Glucagon-mediated energy expenditure elevation
  • Significant clearance of hepatic steatosis markers documented

Chemical Specifications

N/A
N/A

Material Handling & Stability

Laboratory StorageProvided exclusively as a formulated solution. Protect from extreme temperatures.
Aqueous StabilityStable at 2-8°C for up to 30 days after first use. Do not freeze solutions.

Strict Notice

THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.